Another family of direct PADs is that named SMAP (small-molecule activator of PP2A), where the tricyclic sulfonamide DT-061 stands out (Figure 8) as it diminished tumor progression in KRAS-mutated lung cancer, presumably by interacting with the polymorphism of the PP2A-A subunit [155]. Here, PTPA is linked to neoplasm.